RIGEL PHARMACEUTICALS INC — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On July 1, 2026, Rigel Pharmaceuticals announced the appointment of Dr. Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer. Simultaneously, Dr. Hannah resigned from the Board of Directors (where she served since May 2021), and Dr. Lisa Rojkjaer ceased serving as EVP and Chief Medical Officer, separating from the company effective June 25, 2026. No financial terms, severance amounts, or compensation details are disclosed.
Why this rating
Leadership transition at executive level; routine C-suite change. No financial impact disclosed; no evidence of material business disruption or strategic shift.
Extracted items
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.